"现场快报"标签列表

Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Non-Alcoholic(1)2007-11-14

Prevention of Hepatic Fibrosis in a Murine Model of Metabolic Syndrome with Non-Alcoholic(2)2007-11-14

Novel Therapeutic Approach for Nonalcoholic Fatty Liver Disease (NAFLD) using Antiplatelet (5)2007-11-14

Novel Therapeutic Approach for Nonalcoholic Fatty Liver Disease (NAFLD) using Antiplatelet (4)2007-11-14

Novel Therapeutic Approach for Nonalcoholic Fatty Liver Disease (NAFLD) using Antiplatelet (3)2007-11-14

Novel Therapeutic Approach for Nonalcoholic Fatty Liver Disease (NAFLD) using Antiplatelet (2)2007-11-14

Novel Therapeutic Approach for Nonalcoholic Fatty Liver Disease (NAFLD) using Antiplatelet (1)2007-11-14

THE EFFECT OF COMPLETE AND PARTIAL RESPONSE AT WEEK 12 ON SUSTAINED VIROLOGIC RESPONSE(4)2007-11-14

THE EFFECT OF COMPLETE AND PARTIAL RESPONSE AT WEEK 12 ON SUSTAINED VIROLOGIC RESPONSE(2)2007-11-14

THE EFFECT OF COMPLETE AND PARTIAL RESPONSE AT WEEK 12 ON SUSTAINED VIROLOGIC RESPONSE(3)2007-11-14

THE EFFECT OF COMPLETE AND PARTIAL RESPONSE AT WEEK 12 ON SUSTAINED VIROLOGIC RESPONSE(1)2007-11-14

U.S. MULTICENTER PILOT STUDY OF DAILY CONSENSUS INTERFERON (INFERGEN) PLUS RIBAVIRIN FOR (1)2007-11-14

U.S. MULTICENTER PILOT STUDY OF DAILY CONSENSUS INTERFERON (INFERGEN) PLUS RIBAVIRIN FOR (2)2007-11-14

Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon lafa-2a (40KD) (2)2007-11-14

Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon lafa-2a (40KD) (3)2007-11-14

Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon lafa-2a (40KD) (1)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (3)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (4)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (2)2007-11-14

Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction (1)2007-11-14